Protalix Biotherapeutics (De) (PLX) closed at $2.70 on October 15, 2026, up 3.4% from the previous close, on volume of 1,128,122 shares (30-day average 823,549).
Data as of October 15, 2026.
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
PRNewswire (Tue, 8-Sep 6:45 AM ET)
Protalix Posts Record Revenue Growth and Achieves Profitability, Backed by Strong Pipeline Progress
Market Chameleon (Wed, 12-Aug 7:55 AM ET)
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
PRNewswire (Wed, 12-Aug 6:50 AM ET)
PRNewswire (Wed, 5-Aug 6:50 AM ET)
Market Chameleon (Mon, 2-Feb 6:09 AM ET)
Market Chameleon (Fri, 30-Jan 6:09 AM ET)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Protalix Biotherapeutics (De) trades on the AMEX stock market under the symbol PLX.
As of October 16, 2026, PLX stock price declined to $2.66 with 663,073 million shares trading.
PLX has a beta of 1.67, meaning it tends to be more sensitive to market movements. PLX has a correlation of 0.09 to the broad based SPY ETF.
PLX has a market cap of $214.32 million. This is considered a Small Cap stock.
Last quarter Protalix Biotherapeutics (De) reported $20 million in Revenue and $.05 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.06.
In the last 3 years, PLX traded as high as $3.19 and as low as $.82.
The top ETF exchange traded funds that PLX belongs to (by Net Assets): IWM, IWO, VTWO, IWC, DFAS.
PLX has underperformed the market in the last year with a price return of +6.8% while the SPY ETF gained +15.9%. However, in the short term, PLX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +14.2% vs +1.4% return in SPY. But in the last 2 weeks, PLX shares have been beat by the market, returning -0.7% compared to an SPY return of -0.1%.
PLX support price is $2.63 and resistance is $2.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLX shares will trade within this expected range on the day.
